Retatrutide

Triple agonist — GIP, GLP-1, and glucagon receptor

What It Is

An investigational synthetic peptide designed to activate three metabolic-hormone receptor pathways simultaneously, one step beyond the dual-agonist mechanism of tirzepatide.

Proposed Mechanism

Combined GIP/GLP-1/glucagon receptor agonism is hypothesized to increase energy expenditure (via the added glucagon-receptor component) in addition to the appetite and insulin effects seen with GIP/GLP-1 agonists — this remains a research hypothesis under active investigation, not an established mechanism of clinical benefit.

Areas Researchers Are Investigating

• Weight-loss magnitude compared to dual and single-pathway agonists
• Effects on metabolic-associated fatty liver disease
• Cardiometabolic risk factor changes
• Safety and tolerability across dose ranges

Human Evidence

Limited to Phase 2 (and, as of last review, progressing toward/through Phase 3) clinical trial data — smaller and earlier-stage than the semaglutide/tirzepatide evidence base. Trial phase status changes quickly; verify current status at clinicaltrials.gov before publishing anything specific.

Animal / Preclinical Evidence

Standard preclinical pharmacology package consistent with an investigational drug in active clinical development.

Current FDA / Regulatory Status

Not FDA-approved. Investigational — in the manufacturer's (Eli Lilly) clinical trial pipeline as of the last verified review. Not available as an approved prescription product; any consumer-facing sale of this compound for human use would be outside FDA approval.

Known Safety Information

Early trial data has reported a gastrointestinal side-effect pattern similar to other incretin-pathway agents; full safety profile is still being established through ongoing trials. No individualized safety guidance should ever be given for an unapproved investigational compound.

Limitations of Evidence

Early-stage relative to approved GLP-1/GIP drugs; smaller sample sizes; long-term safety data does not yet exist at the scale available for approved products.